Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program

Completed

• Conditions: Healthy

• Registration Number: NCT03628638
• Lead Sponsor: Exact Sciences Corporation

Brief Summary

The primary objective of this study is to establish a control population to assess performance of an investigational diagnostic test targeting lung neoplasms.

Detailed Description

Subjects will be participating in a lung cancer screening program at enrollment. Subjects will have a blood sample collected within 60 days of a low-dose CT scan (LDCT). Subjects with nodules present on the LDCT or subjects with a clean LDCT scheduled for a 12-month follow-up may have another blood draw at 12 months.

Study Timeline

• Study Start: 2017-04-06
• Study First Submitted: 2018-08-09
• Study First Submitted QC: 2018-08-09
• Study First Posted: 2018-08-14
• Primary Completion: 2021-01-31
• Study Completion: 2021-01-31
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-12
• Last Update Posted: 2021-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1718

Inclusion Criteria

1. Subject is male or female, 50 years of age or older.

2. Subject meets one of two lung cancer screening criteria below.

   1. Subject is a candidate for LDCT lung cancer screening and is scheduled for a baseline LDCT scan. There may be circumstances when a patient cannot have an LDCT scan (e.g., due to insurance issues). In these cases, it is allowable for a patient to have a CT scan in order to meet the inclusion criteria. OR
   2. Subject has had previous LDCT scan(s) for lung cancer screening and the most recent LDCT scan prior to enrollment is negative for pulmonary nodules (Lung-RADS category 1, no nodules).

3. Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Exclusion Criteria

1. Subjects with pulmonary nodules on the most recent LDCT scan prior to enrollment (Lung-RADS category 1 nodules with specific calcifications such as complete, central, popcorn, concentric rings and fat containing nodules are excluded).
2. Prior history of cancer within the past 5 years except for non-melanoma skin cancer.
3. Prior removal of the lung, excluding percutaneous lung biopsy.
4. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biomarker Identification	27 months	Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood to detect lung cancer

Trial Locations

Locations (31)

Achieve Clinical Research; 🇺🇸 Birmingham, Alabama, United States

Phoenix Medical Group; 🇺🇸 Peoria, Arizona, United States

Highlands Oncology Group; 🇺🇸 Springdale, Arkansas, United States

NewportNativeMD, Inc.; 🇺🇸 Newport Beach, California, United States

Palmtree Clinical Research, Inc.; 🇺🇸 Palm Springs, California, United States

International Research Partners, LLC; 🇺🇸 Doral, Florida, United States

Clinical Trials of Florida, LLC; 🇺🇸 Miami, Florida, United States

Sarkis Clinical Trials; 🇺🇸 Ocala, Florida, United States

Pasadena Center for Medical Research, Inc.; 🇺🇸 Saint Petersburg, Florida, United States

Sarasota Memorial Hospital; 🇺🇸 Sarasota, Florida, United States

Scroll for more (21 remaining)